our Premium Content: News alerts, weekly reports and conference planners

GENE:

ASXL1 (ASXL Transcriptional Regulator 1)

News alerts, weekly reports and conference planners

Dissecting clonal hematopoiesis in the myeloid compartment of chronic lymphocytic leukemia and Richter transformation. (PubMed, Hemasphere)

Regarding therapy-related toxicities, CH correlated with a higher incidence of Grade ≥ 3 neutropenia (P = 0.004) after venetoclax-based regimens...CH also influenced RT, since CH ASXL1 mutations independently associated with higher RT risk (HR 11.19, 95% CI 4.09-30.62, P < 0.001). Overall, CH in CLL impacts survival, therapeutic toxicity, and transformation risk while also influencing the T-cell immune compartment.

6 days ago

Journal • IO biomarker

TP53 (Tumor protein P53) • ASXL1 (ASXL Transcriptional Regulator 1) • TET2 (Tet Methylcytosine Dioxygenase 2)

TP53 mutation • ASXL1 mutation • TET2 mutation

Venclexta (venetoclax)

Recruitment of BRD4 to the ASXL1 genomic targets depends on the extra-terminal domain of BRD4. (PubMed, Nat Commun)

Genomic data from six cancer types reveals a strong positive ASXL1-BRD4 relationship, with BRD4 occupying the ASXL1 promoter and thus pointing to a possible feed-forward mechanism. Our findings provide mechanistic details by which ASXL1 associates with BRD4 and shed light on the biological significance of this association.

6 days ago

Journal

ASXL1 (ASXL Transcriptional Regulator 1) • KMT2C (Lysine Methyltransferase 2C) • BRD4 (Bromodomain Containing 4)

ASXL1 mutation

Identification of potentially deleterious mutations in gastric cancer using patient-derived xenograft models. (PubMed, Front Genet)

The integrated analysis of longitudinal WES data from primary tumors and matched PDXs enabled the identification of a core set of conserved, potentially deleterious mutations. The four prioritized mutations (PTPRK, PIK3CB, LRP1B, and IGF2R) provide new insights into the genetic landscape of gastric cancer and represent promising candidates for the development of targeted therapeutic strategies.

7 days ago

Preclinical • Journal

TP53 (Tumor protein P53) • ASXL1 (ASXL Transcriptional Regulator 1) • LRP1B (LDL Receptor Related Protein 1B) • PIK3CD (Phosphatidylinositol-4 5-Bisphosphate 3-Kinase Catalytic Subunit Delta) • PIK3CB (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) • IRS2 (Insulin receptor substrate 2) • ERCC5 (ERCC Excision Repair 5 Endonuclease 2) • PDE4DIP (Phosphodiesterase 4D Interacting Protein) • PTPRK (Protein Tyrosine Phosphatase Receptor Type K)

TP53 mutation • ASXL1 mutation

11d

Momelotinib During and After HCT in Myelofibrosis (clinicaltrials.gov)

P1, N=28, Recruiting, Massachusetts General Hospital | Not yet recruiting --> Recruiting

11 days ago

Enrollment open

IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • ASXL1 (ASXL Transcriptional Regulator 1) • SRSF2 (Serine and arginine rich splicing factor 2) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • HLA-B (Major Histocompatibility Complex, Class I, B)

Ojjaara (momelotinib)

13d

The Role and Impact of Non-driver Gene Mutations in Myelofibrosis. (PubMed, Curr Hematol Malig Rep)

This review offers an updated synthesis of the evolving molecular landscape of MF, highlighting how the intricate interplay among genetic alterations has deepened our understanding of disease heterogeneity, allowing refined risk stratification and therapeutic planning. Advances emerging from molecular research and experimental models are progressively translating into clinical practice, promoting more personalized and targeted approaches to the management of MF.

13 days ago

Review • Journal

KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • NRAS (Neuroblastoma RAS viral oncogene homolog) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • DNMT3A (DNA methyltransferase 1) • JAK2 (Janus kinase 2) • RUNX1 (RUNX Family Transcription Factor 1) • SF3B1 (Splicing Factor 3b Subunit 1) • ASXL1 (ASXL Transcriptional Regulator 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • SRSF2 (Serine and arginine rich splicing factor 2) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • CALR (Calreticulin) • ZRSR2 (Zinc Finger CCCH-Type, RNA Binding Motif And Serine/Arginine Rich 2)

14d

Prognostic impact of myelodysplasia-related gene mutations in FLT3-ITD-mutated acute myeloid leukemia. (PubMed, Leukemia)

The allelic ratio of FLT3-ITD did not further stratify OS and RFS in this subgroup. These findings suggest that the prognostic relevance of MRG mutations in FLT3-ITD AML is modulated by NPM1 co-mutational status and mirror findings in AML lacking FLT3-ITD.

14 days ago

Journal

FLT3 (Fms-related tyrosine kinase 3) • NPM1 (Nucleophosmin 1) • RUNX1 (RUNX Family Transcription Factor 1) • SF3B1 (Splicing Factor 3b Subunit 1) • ASXL1 (ASXL Transcriptional Regulator 1) • SRSF2 (Serine and arginine rich splicing factor 2) • BCOR (BCL6 Corepressor) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • STAG2 (Stromal Antigen 2) • ZRSR2 (Zinc Finger CCCH-Type, RNA Binding Motif And Serine/Arginine Rich 2)

FLT3-ITD mutation • FLT3 mutation • NPM1 mutation • SF3B1 mutation • EZH2 mutation • SRSF2 mutation

14d

Clinical characteristics of RUNX1-mutated acute myeloid leukemia patients (PubMed, Zhonghua Xue Ye Xue Za Zhi)

Different induction therapies (chemotherapy/low-intensity treatment) showed no significant impact on the efficacy or prognosis of patients with RUNX1 mutations (P>0.05). Patients with concurrent RUNX1 and DNMT3A or ASXL1 mutations portend a poorer prognosis, and the cooccurrence of FLT3-ITD mutation further leads to inferior therapeutic outcomes.

14 days ago

Retrospective data • Journal

FLT3 (Fms-related tyrosine kinase 3) • NPM1 (Nucleophosmin 1) • DNMT3A (DNA methyltransferase 1) • RUNX1 (RUNX Family Transcription Factor 1) • ASXL1 (ASXL Transcriptional Regulator 1)

FLT3-ITD mutation • NPM1 mutation • RUNX1 mutation • ASXL1 mutation

17d

Mutant ASXL1 Drives Transcriptional Activation and Repression in Human Hematopoiesis. (PubMed, bioRxiv)

Collectively, these studies highlight a highly reproducible model of mutant ASXL1 in the appropriate cell context. Further, they are the first to functionally describe the mutant ASXL1 interactome in the context of the human HSC, identifying new dependencies with therapeutic potential.

17 days ago

Journal

ASXL1 (ASXL Transcriptional Regulator 1) • MECOM (MDS1 And EVI1 Complex Locus) • BRD4 (Bromodomain Containing 4)

ASXL1 mutation

23d

The clinical study on individualized treatment for advanced myeloproliferative neoplasms using integrated multi-omics approaches (ChiCTR2500111453)

P=N/A, N=10, Not yet recruiting, The Second Medical Center of Chinese PLA General Hospital; The Second Medical Center of Chinese PLA General Hospital?

23 days ago

New trial

TP53 (Tumor protein P53) • JAK2 (Janus kinase 2) • ASXL1 (ASXL Transcriptional Regulator 1) • CALR (Calreticulin)

TP53 mutation • ASXL1 mutation • EZH2 mutation

decitabine

27d

Low-VAF TP53-Mutated AML Displays Distinct Biological Features in a Single-Center Cohort. (PubMed, Biomedicines)

TP53-mutated AML with VAF < 10% may represent a biologically distinct subgroup. Further multicenter studies with larger cohorts are needed to validate and refine the VAF threshold for prognostic evaluation and individualized management.

27 days ago

Journal • Tumor mutational burden • IO biomarker

TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • ASXL1 (ASXL Transcriptional Regulator 1) • CD38 (CD38 Molecule) • SRSF2 (Serine and arginine rich splicing factor 2) • CD34 (CD34 molecule)

TP53 mutation • ASXL1 mutation • SRSF2 mutation • Chr del(5q)

28d

ALLO-BAT: Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis (clinicaltrials.gov)

P=N/A, N=90, Active, not recruiting, University Health Network, Toronto | Recruiting --> Active, not recruiting

28 days ago

Enrollment closed

TP53 (Tumor protein P53) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • JAK2 (Janus kinase 2) • ASXL1 (ASXL Transcriptional Regulator 1) • SRSF2 (Serine and arginine rich splicing factor 2) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • CALR (Calreticulin)

TP53 mutation • ASXL1 mutation • EZH2 mutation • SRSF2 mutation • CALR mutation

Jakafi (ruxolitinib) • hydroxyurea

30d

Clinical Characteristics, Molecular Analysis and Survival Outcomes of Patients With Extramedullary Acute Myeloid Leukemia: A Retrospective Single-Center Study. (PubMed, Clin Lymphoma Myeloma Leuk)

Our study demonstrates that patients with eAML subtype have a worse prognosis, unique molecular features and higher tumor burden. Allo-HSCT might be an effective way to improve prognosis. This study provides evidence critical for risk stratification and treatment optimization in eAML.

30 days ago

Retrospective data • Journal

KRAS (KRAS proto-oncogene GTPase) • NPM1 (Nucleophosmin 1) • DNMT3A (DNA methyltransferase 1) • ASXL1 (ASXL Transcriptional Regulator 1) • KMT2A (Lysine Methyltransferase 2A) • TET2 (Tet Methylcytosine Dioxygenase 2) • PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1)

KRAS mutation • NPM1 mutation • ASXL1 mutation • KMT2A mutation • MLL mutation